Histopathological changes following photodynamic therapy in human eyes.
about
An Update on the Ophthalmologic Features in the PhakomatosesAdvances in the treatment of central serous chorioretinopathyApplication of femtosecond ultrashort pulse laser to photodynamic therapy mediated by indocyanine green.Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot studyAge-related macular degeneration: current treatments.A high-throughput biophotonics instrument to screen for novel ocular photosensitizing therapeutic agentsVerteporfin photodynamic therapy of retinal capillary hemangioblastoma in von Hippel-Lindau disease.Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy.Oscillatory photodynamic therapy for choroidal neovascularization and central serous retinopathy; a pilot study.Long-term follow-up of choroidal neovascularization secondary to angioid streaks: case series and literature reviewPhotodynamic Therapy and Intravitreal Bevacizumab with Versus without Triamcinolone for Neovascular Age-related Macular Degeneration; a Randomized Clinical TrialThe chorioretinal damage caused by different half parameters of photodynamic therapy in rabbits.Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy.Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients.Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial.Three-year results of a modified photodynamic therapy procedure (Ironing PDT) for age-related macular degeneration patients with large lesions.Changes in Choroidal Structures in Eyes with Chronic Central Serous Chorioretinopathy after Half-Dose Photodynamic TherapyHistopathological findings in postmortem eyes after photodynamic therapy for choroidal neovascularisation in age-related macular degeneration: report of two cases.Choroidal neovascularisation in pathological myopia: an update in managementSevere decrease in visual acuity with choroidal hypoperfusion after photodynamic therapy.Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.Transient increased exudation after photodynamic therapy of intraocular tumorsRecent perspectives in ocular drug delivery.Subfoveal choroidal thickness after photodynamic therapy in patients with acute idiopathic central serous chorioretinopathyEffects of photodynamic therapy with verteporfin for the treatment of chronic central serous chorioretinopathy: An uncontrolled, open-label, observational studyPhotodynamic therapy of symptomatic choroidal neviPhotodynamic therapy and central serous chorioretinopathy.Microperimetric evaluation of chronic central serous chorioretinopathy after half-dose photodynamic therapyPhotoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapyAnti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization.Macular relocation after photodynamic therapy for recurrent choroidal neovascular membrane: visual results and histopathological findings.Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy.
P2860
Q26738915-16FAAC54-3A66-4624-991D-BABAAD39DA4AQ28088443-4A8BBDE6-3874-49DC-AC0B-DEE75A8DAD33Q33202987-9955555B-F3AB-4B1D-AE7F-386399EF6770Q33239033-6075582A-4247-46EB-9182-6BE8C9D461BEQ33492348-B4B5F415-C2EB-4068-AA3E-6311BC19A94EQ33510871-CB8B7413-784C-480A-9F2A-097298F94CE9Q33520418-CC49A9BE-9B97-4CC6-B976-FD6FAC24C305Q33571004-79C40746-58D4-4CA0-9268-3F1A9A049F1FQ33705962-61B5B57C-A078-4A80-8016-18EB4443E38AQ34210541-6B37B076-F73D-4265-B40B-4245F6103B12Q34357657-7E1DC649-24F7-4389-920D-910F244CFA7DQ35087032-05CBF7ED-1716-4FDA-A192-AFFAAB234732Q35192101-5929F0AD-23CE-4B98-8799-A295C2880661Q35591759-2C6D04B8-6B2F-426F-97CF-CFCA05A91734Q35749002-7216C074-2FB6-4D03-A559-97393673CCB8Q35782233-D1BB8995-6A06-4A27-A38C-F9D215B0A640Q35978854-C2F247A9-3DF2-4512-8750-10E963046534Q36135515-915AD062-C1B5-413C-8294-2F788BDC8B01Q36172252-E912BFB5-0155-4EFF-B528-DFAFE4ABF4A4Q36290241-7790075C-0AD6-43EA-BF5D-C0047EA651A4Q36516474-D2D6FADD-6437-429E-A8F9-A98CCC71D23AQ36685488-9792BFF5-E6A4-40B2-8B84-08DE907BFED7Q36743064-C5B73FD8-18EC-4622-BCC3-D5C6F54D9F8CQ37256549-C656A337-014E-473F-998E-6AADBDC10860Q37478532-E49B8E37-854F-4AF1-9829-7229C150422FQ37667426-2C7E2DED-BC43-4C6E-AB5C-76709222D8CAQ37973730-0F5E5AFF-BBC6-45C7-AEEA-C8C02BFF5DC4Q41990230-3C70665B-B879-483A-945E-6D1D0477EF63Q42093637-3B485012-9701-4872-885A-270C09225E48Q42237072-3BADDCCA-6FB2-4C52-96B6-CD1626F0E95EQ42280535-7BD1444C-E6D7-469C-9293-DC5AD0EDB12BQ43008452-9DD1A9DF-3D17-4FD8-9B90-000E95892AB5Q48372058-70AA9FDC-6FA1-4FBB-8BEC-6908FB38E816
P2860
Histopathological changes following photodynamic therapy in human eyes.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Histopathological changes following photodynamic therapy in human eyes.
@en
Histopathological changes following photodynamic therapy in human eyes.
@nl
type
label
Histopathological changes following photodynamic therapy in human eyes.
@en
Histopathological changes following photodynamic therapy in human eyes.
@nl
prefLabel
Histopathological changes following photodynamic therapy in human eyes.
@en
Histopathological changes following photodynamic therapy in human eyes.
@nl
P2093
P1433
P1476
Histopathological changes following photodynamic therapy in human eyes
@en
P2093
Arne Viestenz
Gottfried O H Naumann
Horst Laqua
Ursula Schlötzer-Schrehard
P304
P407
P577
2002-06-01T00:00:00Z